Science

Nina Niu Sanford: Trends in dose escalation for definitive chemoRT in esophagus cancer

Nina Niu Sanford/utswmed.org

Feb 8, 2025, 07:22

Nina Niu Sanford: Trends in dose escalation for definitive chemoRT in esophagus cancer

Nina Niu Sanford, Assistant Professor and Chief of Gastrointestinal Radiation Oncology at Harvard/Brigham and Women’s Hospital/Massachusetts General Hospital, shared her recent article on X:

“We looked at trends in dose escalation for definitive chemoRT in esophagus cancer from 2006-2016.

By that point, 50.4 already most common dose, but 56% of cervical esophagus SCC received >50.4 Gy.

Would be interesting to see practice patterns now post ARTDECO, PRODIGE 26, etc.”

Patterns of Dose Escalation Among Patients With Esophageal Cancer Undergoing Definitive Radiation Therapy: 2006-2016.

Authors: Elizabeth R Zhang-Velten, et al.

Nina Niu Sanford: Trends in dose escalation for definitive chemoRT in esophagus cancer

Brigham and Women's Hospital cancer chemoRT Elizabeth R Zhang-Velten esophageal cancer esophagus cancer fight against cancer Global fight against cancer Massachusetts General Hospital Nina Niu Sanford OncoDaily Oncology radiation therapy RadOnc

Stanley Tucci and Throat Cancer: How He Went Against, How He Survived, and More

Senator John Fetterman Responds to Oncodaily on Pediatric Oncology Funding

Does Processed Meat Cause Cancer? Myths and Facts

Global Health Dialogues with Princess Dina Mired | Episode 1: Dr. Firas Al-Hawari

NEW PAPER ALERT: ESOPEC trial on Perioperative Chemotherapy or Preoperative Chemoradiotherapy in Esophageal Cancer